Skip to main content
Equibles
DMRA logo

DMRA · Damora Therapeutics, Inc. · Metrics

Track DMRA — free

Use DMRA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research DMRA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$28.10 +1.26 (+4.69%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 10, 2026

Substantial doubt about the company's ability to continue as a going concern.

“If we are unable to raise additional capital when needed, that could raise substantial doubt about our ability to continue as a going concern.”
View the 10-Q filed Aug 10, 2026
Market Cap
$1.73B
Shares
61.74M

DMRA metrics

50 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$28.10
Market cap
$1.73B

Price action

20 metrics
Price change (1W)
-6.5%
Price change (30D)
-8.6%
Price change (3M)
+35.2%
Price change (6M)
+6.7%
Price change (YTD)
+22.1%
Price change (1Y)
+903.6%
Trailing year
Price change (5Y)
—
52-week high
$34.14
52-week low
$2.75
Change from 52-week high
-17.7%
Change from 52-week low
+921.8%
Annualized volatility
474.9%
Annualized volatility (3M)
77.3%
Beta
2.2
RSI (14D)
45.8
Price vs SMA 50
-5.7%
Price vs SMA 200
+7.1%
Avg volume (3M)
575,113
Relative volume
0.9
Average dollar volume
$15.77M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
61.74M

Valuation

12 metrics
P / E (TTM)
3.8
Trailing earnings · reciprocal yield 26.7%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
3.4
reciprocal yield 29.7%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-15.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$270.66M
Net income (TTM)
−$262.83M
Trailing 12 months
Diluted EPS (TTM)
$7.49
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$150.49

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+4,521.1%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-50.9%
Return on assets
-48.3%
Debt / equity
—
Current ratio
19.7
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
19.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$540.51M
Total assets
$543.64M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$44.52M
Capital expenditures (TTM)
—
R&D (TTM)
$74.05M
SG&A (TTM)
—
Stock compensation (TTM)
$9.93M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
104
13F filer change QoQ
+39
Institutional ownership
104.5%

Short interest

3 metrics
Short interest
6.7%
Latest settlement · 13.3 days to cover
Days to cover
13.3d
Short-squeeze score
73 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$7,345
Insider-sentiment score
60 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1800315 CUSIP G2646Y104 13F (30d) 52 filings 52 filers Visit website Investor relations